Breaking News Instant updates and real-time market news.

BIIB

Biogen

$291.60

68.03 (30.43%)

13:39
10/22/19
10/22
13:39
10/22/19
13:39

Biogen price target raised to $310 from $255 at Jefferies

Jefferies analyst Michael Yee raised his price target for Biogen to $310 from $255 while keeping a Hold rating on the shares. The surprise announcement to file for Alzheimer's is good for investors, but will lead to another binary decision by the end of 2020 and "some time to wait," Yee tells investors in a research note. The analyst, however, likes the "call option" and believes the argument to FDA is "decent based on data," but cautions the agency "could easily ask for another study. Yee, who thinks Biogen doing acquisitions is now more likely, does not want to chase the shares on today's rally.

  • 22

    Oct

BIIB Biogen
$291.60

68.03 (30.43%)

10/22/19
CANT
10/22/19
NO CHANGE
Target $250
CANT
Neutral
Cantor 'inclined to believe' Biogen has 'strong evidence' to advance aducanumab
Cantor Fitzgerald analyst Alethia Young said she is reviewing her model for Biogen based on today's news, but she is "more inclined to believe that there is reasonably strong evidence for the company to move forward with a BLA filing" for aducanumab in Alzheimer's. She does not think, given what she knows about Biogen management, that the company would be discussing a filing strategy on a failed call unless they had significant reassurance from the FDA, which Young notes saw the full analysis post the futility analysis. She also thinks this morning's jump in the stock is "warranted" as she believes investors will probably move to 50%-60% confidence, at least, for a potential approval of aducanumab, Young added. She has a Neutral rating and $250 price target on Biogen shares as of the time of her "quick take" note on this morning's news.
10/22/19
OPCO
10/22/19
NO CHANGE
Target $334
OPCO
Outperform
Biogen price target raised to $334 from $280 at Oppenheimer
Oppenheimer analyst Jay Olson said Biogen offered detailed explanations regarding flaws in its previous futility analysis and how subsequent analysis of additional data revealed EMERGE as the first positive Phase 3 pivotal trial for a potentially Alzheimer's disease-modifying drug that could lead to regulatory approval. The analyst, who is optimistic about the prospects for aducanumab, restored the drug in his model with a 50% probability of success, leading him to increase his price target for Biogen shares to $334 from $280. Olson keeps an Outperform rating on Biogen.
10/22/19
STFL
10/22/19
NO CHANGE
Target $296
STFL
Hold
Biogen price target raise to $296 from $236 at Stifel
Stifel analyst Paul Matteis raised his price target for Biogen to $296 from $236 and maintained a Hold rating, reflecting a 33% probability of approval for aducanumab. In a research note to investors, Matteis says he attributes "legitimate credit" to Biogen for having already engaged the FDA in two meetings, but says "a battery of questions remains" regarding the aducanumab dataset that will go into the BLA. He views the EMERGE data as "clearly positive," but feels the ENGAGE data look "definitively negative," but is "unconfident" that the ENGAGE subgroup salvages the overall narrative.
10/22/19
PIPR
10/22/19
NO CHANGE
Target $305
PIPR
Neutral
Biogen price target raised to $305 from $250 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Biogen to $305 from $250 after news that management intends to file for aducanumab approval. While investors "can rightly quibble with the chain of events that got us here," this is Alzheimer's and, "like a number of highly underserved disease states, FDA will likely exercise flexibility," Raymond tells investors in a research note. The analyst expects a filing in early 2020, FDA acceptance of the file and ultimately a panel committee "to keep hope alive" for aducanumab. Raymond, however, thinks handicapping the approval is "difficult at best." That said, "assuming a highly successful launch," aducanumab adds ~$70 to his sum-of-parts analysis. He remains on the sidelines with a Neutral rating on Biogen.

TODAY'S FREE FLY STORIES

ESYJY

easyJet

$0.00

(0.00%)

20:35
11/19/19
11/19
20:35
11/19/19
20:35
Initiation
easyJet initiated at Goldman Sachs »

easyJet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSEX

Middlesex Water

$62.07

1.5 (2.48%)

20:31
11/19/19
11/19
20:31
11/19/19
20:31
Syndicate
Middlesex Water 661K share Spot Secondary priced at $60.50 »

Baird is acting as lead…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

DLAKY

Lufthansa

$0.00

(0.00%)

20:29
11/19/19
11/19
20:29
11/19/19
20:29
Initiation
Lufthansa initiated at Goldman Sachs »

Lufthansa initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$110.86

0.27 (0.24%)

, LOW

Lowe's

$113.41

-1.62 (-1.41%)

20:25
11/19/19
11/19
20:25
11/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TGT

Target

$110.86

0.27 (0.24%)

LOW

Lowe's

$113.41

-1.62 (-1.41%)

NTES

NetEase

$288.77

-1.33 (-0.46%)

CPRT

Copart

$86.33

0.32 (0.37%)

LB

L Brands

$17.19

-0.67 (-3.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

ICAGY

IAG

$0.00

(0.00%)

20:23
11/19/19
11/19
20:23
11/19/19
20:23
Initiation
IAG initiated at Goldman Sachs »

IAG initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYAAY

Ryanair

$86.27

0.52 (0.61%)

20:20
11/19/19
11/19
20:20
11/19/19
20:20
Initiation
Ryanair initiated at Goldman Sachs »

Ryanair initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXFR

Luxfer

$17.57

0.16 (0.92%)

20:11
11/19/19
11/19
20:11
11/19/19
20:11
Initiation
Luxfer initiated at B. Riley FBR »

Luxfer initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAL

Valaris

$3.69

-0.515 (-12.26%)

20:09
11/19/19
11/19
20:09
11/19/19
20:09
Initiation
Valaris initiated at Deutsche Bank »

Valaris initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIG

Transocean

$4.66

-0.16 (-3.32%)

20:03
11/19/19
11/19
20:03
11/19/19
20:03
Initiation
Transocean initiated at Deutsche Bank »

Transocean initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$19.29

-0.24 (-1.23%)

19:58
11/19/19
11/19
19:58
11/19/19
19:58
Initiation
TechnipFMC initiated at Deutsche Bank »

TechnipFMC initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$34.31

-0.36 (-1.04%)

19:53
11/19/19
11/19
19:53
11/19/19
19:53
Initiation
Schlumberger initiated at Deutsche Bank »

Schlumberger initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTEN

Patterson-UTI

$8.49

-0.095 (-1.11%)

19:45
11/19/19
11/19
19:45
11/19/19
19:45
Initiation
Patterson-UTI initiated at Deutsche Bank »

Patterson-UTI initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFE

Safehold

$34.59

-1.33 (-3.70%)

19:38
11/19/19
11/19
19:38
11/19/19
19:38
Syndicate
Safehold 3M share Secondary priced at $34.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 20

    Nov

HP

Helmerich & Payne

$38.39

-0.45 (-1.16%)

19:36
11/19/19
11/19
19:36
11/19/19
19:36
Initiation
Helmerich & Payne initiated at Deutsche Bank »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$19.89

-0.26 (-1.29%)

19:31
11/19/19
11/19
19:31
11/19/19
19:31
Initiation
Halliburton initiated at Deutsche Bank »

Halliburton initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

BKR

Baker Hughes

$22.01

-0.155 (-0.70%)

19:24
11/19/19
11/19
19:24
11/19/19
19:24
Initiation
Baker Hughes initiated at Deutsche Bank »

Baker Hughes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHAT

Phathom Pharmaceuticals

$24.79

-0.09 (-0.36%)

19:23
11/19/19
11/19
19:23
11/19/19
19:23
Initiation
Phathom Pharmaceuticals initiated at Evercore ISI »

Phathom Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHW

Sherwin-Williams

$584.48

-1.13 (-0.19%)

19:20
11/19/19
11/19
19:20
11/19/19
19:20
Downgrade
Sherwin-Williams rating change at Edward Jones »

Sherwin-Williams…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$311.95

-0.06 (-0.02%)

, SPX

S&P 500

$0.00

(0.00%)

19:17
11/19/19
11/19
19:17
11/19/19
19:17
Periodicals
Commerce Sec Ross says China trade talks still work in progress, Bloomberg says »

U.S. Commerce Secretary…

SPY

SPDR S&P 500 ETF Trust

$311.95

-0.06 (-0.02%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRY

Berry Petroleum

$8.90

-2.405 (-21.27%)

19:10
11/19/19
11/19
19:10
11/19/19
19:10
Downgrade
Berry Petroleum rating change at KeyBanc »

Berry Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYMT

New York Mortgage

$6.25

0.015 (0.24%)

19:05
11/19/19
11/19
19:05
11/19/19
19:05
Syndicate
New York Mortgage 25M share Spot Secondary priced at $6.10 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

LNG

Cheniere Energy

$59.77

-0.69 (-1.14%)

19:01
11/19/19
11/19
19:01
11/19/19
19:01
Hot Stocks
Cheniere Energy CEO buys 8.4K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

SQ

Square

$66.43

0.68 (1.03%)

18:57
11/19/19
11/19
18:57
11/19/19
18:57
Hot Stocks
Square CFO: Our mission is economic empowerment »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 10

    Dec

  • 26

    Feb

AVID

Avid Technology

$7.74

0.15 (1.98%)

, DL

China Distance Education

$7.15

0.05 (0.70%)

18:56
11/19/19
11/19
18:56
11/19/19
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Avid…

AVID

Avid Technology

$7.74

0.15 (1.98%)

DL

China Distance Education

$7.15

0.05 (0.70%)

ESE

Esco Technologies

$86.71

1.94 (2.29%)

BCRX

BioCryst

$2.03

0.33 (19.41%)

CTMX

CytomX Therapeutics

$5.15

-0.03 (-0.58%)

ENDP

Endo

$4.44

-0.02 (-0.45%)

AVYA

Avaya

$12.11

-0.22 (-1.78%)

BKR

Baker Hughes

$22.01

-0.155 (-0.70%)

URBN

Urban Outfitters

$28.73

-1.43 (-4.74%)

ALC

Alcon

$59.00

0.105 (0.18%)

ORGO

Organogenesis

$8.01

0.02 (0.25%)

AMRN

Amarin

$22.74

0.11 (0.49%)

CRSP

Crispr Therapeutics

$68.46

9.94 (16.99%)

MGP

MGM Growth

$32.46

-0.39 (-1.19%)

RIG

Transocean

$4.66

-0.16 (-3.32%)

NYMT

New York Mortgage

$6.25

0.015 (0.24%)

MSEX

Middlesex Water

$62.07

1.5 (2.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 02

    Dec

  • 02

    Dec

  • 05

    Dec

  • 07

    Dec

  • 28

    Dec

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

NVDA

Nvidia

$207.90

-4.36 (-2.05%)

, MLNX

Mellanox

$114.40

0.245 (0.21%)

18:47
11/19/19
11/19
18:47
11/19/19
18:47
Hot Stocks
Nvidia CEO: We're at the beginning of the artificial intelligence revolution »

In an interview on…

NVDA

Nvidia

$207.90

-4.36 (-2.05%)

MLNX

Mellanox

$114.40

0.245 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 06

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.